Payment overview · 2025
General Payments
$830.13
40 reported records · 10 companies
Healthcare provider profile · identity verified
Stewart Bae, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · FLUSHING, NY · NPI 1205910999
Verified facts
What the public records show
CMS Open Payments records show Stewart Bae, M.D. received $830.13 in general payments during 2025 across 40 reported records.
Novo Nordisk Inc accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rayaldee, Velphoro.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Lokelma by this doctor in 2024.
Fresenius USA Manufacturing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 157 records involving 87 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Velphoro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rayaldee by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.19 | 18.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.09 | 17.2% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $137.31 | 16.5% | 10 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $103.73 | 12.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.79 | 10.0% | 4 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $65.53 | 7.9% | 3 | 2025 |
| Fresenius USA Manufacturing, Inc. | Unresolved — no canonical attribution shown | $45.21 | 5.5% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $39.38 | 4.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.63 | 4.5% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.27 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $726.40 | 34 |
| Education | $103.73 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $143.09 | 5 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $137.31 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $121.24 | 4 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $103.73 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.79 | 4 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $65.53 | 3 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Manufacturing, Inc. | $45.21 | 2 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $39.38 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.95 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.52 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $19.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 149 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VELPHORO velphoro |
2025 | Velphoro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
149 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| Fresenius USA Manufacturing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 157 supporting records · 87 recipient NPIs · example record 1241710487 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 676 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 584 | 159 |
| Metformin Hcl | Metformin Hcl | 447 | 122 |
| Vascepa | Icosapent Ethyl | 263 | 65 |
| Losartan Potassium | Losartan Potassium | 257 | 67 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 237 | 58 |
| Alendronate Sodium | Alendronate Sodium | 220 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 49 |
| Farxiga | Dapagliflozin Propanediol | 149 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 46 |
| Januvia | Sitagliptin Phosphate | 135 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 27 |
| Gabapentin | Gabapentin | 88 | 28 |
| Sevelamer Carbonate | Sevelamer Carbonate | 87 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 22 |
| Omeprazole | Omeprazole | 75 | 17 |
| Calcitriol | Calcitriol | 73 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 19 |
| Lokelma | Sodium Zirconium Cyclosilicate | 68 | 15 |
| Celecoxib | Celecoxib | 64 | 24 |
| Atenolol | Atenolol | 63 | 15 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 58 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 17 |
| Donepezil Hcl | Donepezil Hcl | 56 | 13 |
| Glipizide | Glipizide | 56 | 13 |
| Nifedipine Er | Nifedipine | 53 | 16 |
| Montelukast Sodium | Montelukast Sodium | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 17 |
| Simvastatin | Simvastatin | 48 | 13 |
| Carvedilol | Carvedilol | 45 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | suppressed |
| Allopurinol | Allopurinol | 39 | 13 |
| Jardiance | Empagliflozin | 39 | 12 |
| Lisinopril | Lisinopril | 39 | 14 |
| Alprazolam | Alprazolam | 38 | 12 |
| Trazodone Hcl | Trazodone Hcl | 38 | 11 |
| Ozempic | Semaglutide | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Furosemide | Furosemide | 36 | 13 |
| Acarbose | Acarbose | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Eliquis | Apixaban | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 32 | 16 |
| Azithromycin | Azithromycin | 28 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Meloxicam | Meloxicam | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Prolia | Denosumab | 24 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 11 |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Rayaldee | Calcifediol | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Prednisone | Prednisone | 19 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Procrit | Epoetin Alfa | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | 11 |
| Glimepiride | Glimepiride | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $830.13 · 40 records | Novo Nordisk Inc | FABRAZYME, FARXIGA, Fabhalta, GVOKE HYPOPEN, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, RAYALDEE, REPATHA, VELPHORO, Vanrafia, Veltassa, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error